IMUBIND® Tissue PAI-1 ELISA（组织

INTENDED USE
The IMUBIND® Tissue PAI-1 ELISA kit is an enzyme-linked immunoassay for the determination of human PAI-1 in tissue extracts and cell culture supernatants. The assay detects latent (inactive) and active forms of PAI-1 and PAI-1 complexes and is insensitive to PAI-2.
This assay is for research use only. It is not intended for diagnostic or therapeutic procedures.

EXPLANATION OF THE TEST
Plasminogen activator inhibitor type 1 (PAI-1), a primary regulator in fibrinolysis,1,2 has been found in a number of different cell types, i.e. macrophages/monocytes, platelets, vascular endothelial and adipose tissue of the heart and lungs.3 PAI-1 has been implicated along with urokinase-type plasminogen activator (uPA) as a prognostic factor for relapse-free and overall survival in breast cancer and gastric cancer patients. In patients diagnosed with primary breast cancer, PAI-1 ranks second to only lymph node status as a prognostic factor for Disease-free Survival (DFS) and Overall Survival (OS), with the established prognostic factors of node status, grading, tumor size and hormone receptor status.7 In ancillary nodenegative patients, PAI-1 ranks highest with the established factors of tumor size, grading and hormone receptor status and experimental factors such as uPA (Urokinase Plasminogen Activator), Cathepsin D and S-Phase Fraction.8

It has been shown that a combination of PAI-1 and uPA further advances the delineation of patients having a low or high risk for relapse independent of the classical risk factors. Therefore by combining PAI-1 and uPA levels in tissue extracts a more individualized estimation of prognosis becomes possible in breast cancer patients.4-8 PAI-1 positivity may also serve as a prognostic factor for completely resected gastric cancer patients.9